- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CD44/ CDW44/ CSPG8 monoclonal antibody
Anti-CD44/ CDW44/ CSPG8 antibody for FACS & in-vivo assay
Go to CD44/CD44 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T78319-Ab-1/ GM-Tg-hg-T78319-Ab-2 | Anti-Human CD44 monoclonal antibody | Human |
| GM-Tg-rg-T78319-Ab-1/ GM-Tg-rg-T78319-Ab-2 | Anti-Rat CD44 monoclonal antibody | Rat |
| GM-Tg-mg-T78319-Ab-1/ GM-Tg-mg-T78319-Ab-2 | Anti-Mouse CD44 monoclonal antibody | Mouse |
| GM-Tg-cynog-T78319-Ab-1/ GM-Tg-cynog-T78319-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD44 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T78319-Ab-1/ GM-Tg-felg-T78319-Ab-2 | Anti-Feline CD44 monoclonal antibody | Feline |
| GM-Tg-cang-T78319-Ab-1/ GM-Tg-cang-T78319-Ab-2 | Anti-Canine CD44 monoclonal antibody | Canine |
| GM-Tg-bovg-T78319-Ab-1/ GM-Tg-bovg-T78319-Ab-2 | Anti-Bovine CD44 monoclonal antibody | Bovine |
| GM-Tg-equg-T78319-Ab-1/ GM-Tg-equg-T78319-Ab-2 | Anti-Equine CD44 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T78319-Ab-1/ GM-Tg-hg-T78319-Ab-2; GM-Tg-rg-T78319-Ab-1/ GM-Tg-rg-T78319-Ab-2; GM-Tg-mg-T78319-Ab-1/ GM-Tg-mg-T78319-Ab-2; GM-Tg-cynog-T78319-Ab-1/ GM-Tg-cynog-T78319-Ab-2; GM-Tg-felg-T78319-Ab-1/ GM-Tg-felg-T78319-Ab-2; GM-Tg-cang-T78319-Ab-1/ GM-Tg-cang-T78319-Ab-2; GM-Tg-bovg-T78319-Ab-1/ GM-Tg-bovg-T78319-Ab-2; GM-Tg-equg-T78319-Ab-1/ GM-Tg-equg-T78319-Ab-2 |
| Products Name | Anti-CD44 monoclonal antibody |
| Format | mab |
| Target Name | CD44 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CD44 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-INN-763 | Pre-Made Bivatuzumab Biosimilar, Whole Mab, Anti-Cd44 Antibody: Anti-CDW44/CSPG8/ECMR-III/HCELL/HUTCH-I/IN/LHR/MC56/MDU2/MDU3/MIC4/Pgp1 therapeutic antibody |
| Target Antigen | Products Developing | Multi-species CD44/ CDW44/ CSPG8 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMLP002663 | human CD44 Lentivirus plasmid |
| ORF Viral Vector | vGMLP002663 | human CD44 Lentivirus particle |
| ORF Viral Vector | pGMLPm004030 | mouse Cd44 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm004030 | mouse Cd44 Lentivirus particle |
Target information
| Target ID | GM-T78319 |
| Target Name | CD44 |
| Gene ID | 960,12505,25406,717204,403939,101098744,281057,100034221 |
| Gene Symbol and Synonyms | CD44,CD44A,CDW44,CSPG8,ECM-III,ECMR-III,H-CAM,HCELL,HERMES,Hermes-1,HUTCH-1,HUTCH-I,IN,LHR,Ly-24,MC56,MDU2,MDU3,METAA,MIC4,Pgp-1,Pgp1,RHAMM |
| Uniprot Accession | P16070,P26051,Q28284,Q29423,Q05078 |
| Uniprot Entry Name | CD44_HUMAN,CD44_RAT,CD44_CANLF,CD44_BOVIN,CD44_HORSE |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Immuno-oncology Target, INN Index |
| Disease | colon cancer, Malignant neoplasm of bladder, Congenital occlusion of ureteropelvic junction, IgA glomerulonephritis, Lung cancer |
| Gene Ensembl | ENSG00000026508 |
| Target Classification | Checkpoint-Immuno Oncology |
The target: CD44, gene name: CD44, also named as CDW44, CSPG8, ECMR-III, HCELL, HUTCH-I, IN, LHR, MC56, MDU2, MDU3, MIC4, Pgp1. The protein encoded by this gene is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration. It is a receptor for hyaluronic acid (HA) and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). This protein participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. Transcripts for this gene undergo complex alternative splicing that results in many functionally distinct isoforms, however, the full length nature of some of these variants has not been determined. Alternative splicing is the basis for the structural and functional diversity of this protein, and may be related to tumor metastasis. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
